

ABSORB Bioresorbable Vascular Everolimus Scaffold (BVS) in Complicated Coronary Intervention ----Experiences from Macao



生物可降解依维莫司聚乳酸模架在复 杂冠脉中的运用-澳门经验

> 邓锡伟 MD,MACC Chief Consultant in Cardiology Kiang Wu Hospital, Macau

Revolutions in Interventional Cardiology


Revolution One	Revolution Two	Revolution Three	Revolution Four
Balloon Angioplasty (PTCA)	Bare Metal Stents (BMS)	Drug Eluting Stents (DES)	Bioresorbable Stent
	S.S.S.S		
1977	1988	2001	2011

Revolution Four

ABSORB Bioresorbable Vascular Scaffold (BVS)



Absorb Worldwide Exposure by End of 2013




Characteristics of BVS





BVS System Components






- Poly(L-lactide)
- Naturally resorbed, fully metabolized
- Fully rebsorbed in about 2 years







Bioresorbable Coating (PDLLA)

- Poly(D,L-lactide)
- Naturally resorbed, fully metabolized

Everolimus


• Similar dose density and release rate to XIENCE V

XIENCE Delivery System

• World-class deliverability



Bioresorbable Scaffold (PLLA) plus Bioresorbable Coating (PDLLA)




Everolimus / PDLLA Coating

- Non-crystalline
- Everolimus: PDLLA = 1 : 1
- Polymer coating with thickness of 2-4 μm2-4
 - Controlled drug delivery system

PLLA Scaffold

- High crystallinity
- Guarantee integrity of the system
- Sufficient radical strength

BVS: Phases of Functionality






Stent Feature Matrix

	Bare-Metal Stents	Drug-eluting Stent	Bioabsorbable drug- eluting Stent
Reduced Dual- Antiplatelet Therapy			
No neointimal hyperplasia			
Restoration of Vasomotion			
Material (Biocompatible)			


Lobodzinski, S. S. (2008). Bioabsorbable Coronary Stents. Cardiology Journal, 15(6), 569-571.

Porcine Coronary Histologic Studies

BVS (2X)



CYPHER (2X)







Data on file at Abbott Vascular

BVS STENT

"Radio-lucent" and "radio-opaque" coronary stents characterized by multislice computed tomography



Little vascular inflammatory response to BVS



Weaker inflammatory response than Cypher

Inflammatory response can almost be ignored after one year.

Inflammation score≤ 1 according to porcine coronary studies

100 Cypher 90 Foreign Body Response 80 70 60 50 40 Struts, 30 20 % 10 ф. 3 6 9 12 18 24 36 48 1 Time (months)

BVS

Weak foreign body response (FBR) after implantation

FBR vanishes after 2yrs as BVS dissolves completely

Tests performed by and data on file at Abbott Vascular.

Advantages of BVS

- Vasomotion
- Arterial remodelling and late lumen enlargement
- Side branch jailing
- Conformability
- Edge vascular response
- Incomplete stent apposition




Figure 6. The edge vascular response as a consequence of iatrogenic, device-related and biologic factors.



Patient Considerations for Initiating Therapy with a Fully BVS

Younger patients facing their first revascularization procedure

- Younger patients could potentially have a treated vessel that is restored to a more natural state; absence of a permanent metal stent leaves the vessel segment unconstrained, enabling it to respond to physiological demands
 - Potential for reducing the need for prolonged DAPT
 - Generally more active with the potential for greater benefit from a naturally functional vessel
- Younger patients may need future interventions that can be complicated or compromised by a permanent metal stent
 - Absence of a permanent implant may preserve more options for future interventions, whether PCI or CABG
 - CABG is also complicated by the presence of stents¹⁻³
 - MSCT imaging may allow non-invasive determination of potential retreatment strategies



Clinical Trials





The ABSORB Clinical Trial Program






Optimization of BVS design






Photos taken by and on file at Abbott Vascular.

- Uniform stent struts distribution
- More balanced vascular wall support
- Sufficient radical strength
- Lower late stent area loss
- Stored under indoor temperature
- Improved in controllability of delivery system
- Preserved:
 - Material of coating & backbone
 - Thickness of struts
 - Velocity of drug release
 - Time of complete absorption





Absorb Cohort A



Device ---- 3.0 x 12mm scaffolds (3.0 x18mm* scaffolds available after enrolment start)